within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK02_Canagliflozin;

model Canagliflozin
  extends Pharmacolibrary.Drugs.ATC.A.A10BK02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BK02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus in adults, improving glycemic control by reducing renal glucose reabsorption and promoting urinary glucose excretion. It is an approved, widely used oral antidiabetic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, both male and female, following a single 300 mg oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Devineni, D, et al., &amp; Mamidi, RN (2015). Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. <i>Clinical pharmacology in drug development</i> 4(4) 295–304. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.162&quot;>10.1002/cpdd.162</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27136910/&quot;>https://pubmed.ncbi.nlm.nih.gov/27136910</a></p></li><li><p>Hu, W, et al., &amp; Liu, Z (2020). Pharmacokinetics and bioequivalence of two oral formulations of canagliflozin after single-dose administration in healthy Chinese subjects . <i>International journal of clinical pharmacology and therapeutics</i> 58(1) 57–65. DOI:<a href=&quot;https://doi.org/10.5414/CP203437&quot;>10.5414/CP203437</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31347489/&quot;>https://pubmed.ncbi.nlm.nih.gov/31347489</a></p></li><li><p>Frampton, JE (2018). Empagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 78(10) 1037–1048. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0937-z&quot;>10.1007/s40265-018-0937-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29946963/&quot;>https://pubmed.ncbi.nlm.nih.gov/29946963</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Canagliflozin;
